Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Biotechnology
|GILD||Gilead Sciences, Inc.||-1.82%||67.81||1.0%||$457.06m|
|REGN||Regeneron Pharmaceuticals, Inc.||-0.60%||614.38||2.7%||$380.02m|
|VRTX||Vertex Pharmaceuticals, Inc.||-0.97%||228.61||1.9%||$333.31m|
|SNSS||Sunesis Pharmaceuticals, Inc.||-4.17%||2.76||0.7%||$192.93m|
|EXAS||EXACT Sciences Corp.||-0.13%||76.03||17.9%||$166.25m|
|ARNA||Arena Pharmaceuticals, Inc.||-0.55%||91.01||13.7%||$134.19m|
|ALNY||Alnylam Pharmaceuticals, Inc.||-0.22%||138.31||8.2%||$127.21m|
|BBIO||BridgeBio Pharma, Inc.||-2.05%||11.46||0.0%||$102.72m|
Altamira Therapeutics Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. It operates through Switzerland and Australia geographical segments. Its product pipeline includes AM-125, AM-201, AM301, Sonsuvi, and Keyzilen. The company was founded by Thomas Meyer in April 2003 and is headquartered in Hamilton, Bermuda.